Combination of the PAM4 and CA19-9 biomarkers to improve the detection of pancreatic adenocarcinoma.

被引：0
|
作者：
Gold, David V.
Gaedcke, Jochen
Ghadimi, B. Michael
Goggins, Michael
Hruban, Ralph H.
Liu, Mengling
Newsome, Guy
Goldenberg, David M.
机构：
[1] Ctr Mol Med & Immunol, Garden State Canc Ctr, Morris Plains, NJ USA
[2] Univ Goettingen, Univ Med Ctr, Gottingen, Germany
[3] Johns Hopkins Med Inst, Baltimore, MD USA
[4] New York Univ, Med Ctr, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 04期
关键词：
D O I：
10.1200/jco.2012.30.4_suppl.164
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
164
引用
收藏
页数：2
相关论文
共 50 条
  • [31] CA19-9 RIA FOR DIFFERENTIATION BETWEEN PANCREATIC ADENOCARCINOMA AND CHRONIC-PANCREATITIS ENDOCRINE PANCREATIC TUMORS
    KLAPDOR, R
    LEHMANN, U
    BAHLO, M
    GRETEN, H
    VONACKEREN, H
    DALLEK, U
    KRAAS, E
    DIGESTION, 1983, 28 (01) : 39 - 39
  • [32] CA-19-9 AND PANCREATIC ADENOCARCINOMA
    SAFI, F
    BEGER, HG
    BITTNER, R
    BUCHLER, M
    KRAUTZBERGER, W
    CANCER, 1986, 57 (04) : 779 - 783
  • [33] Combined detection of CA19-9 and B7-H4 in the diagnosis and prognosis of pancreatic cancer
    Xu, Xiangming
    Xiao, Yufei
    Hong, Bo
    Hao, Bing
    Qian, Yun
    CANCER BIOMARKERS, 2019, 25 (03) : 251 - 257
  • [34] Validation of N-glycan markers that improve the performance of CA19-9 in pancreatic cancer
    Yun-Peng Zhao
    Ping-Ting Zhou
    Wei-Ping Ji
    Hao Wang
    Meng Fang
    Meng-Meng Wang
    Yue-Peng Yin
    Gang Jin
    Chun-Fang Gao
    Clinical and Experimental Medicine, 2017, 17 : 9 - 18
  • [35] Validation of N-glycan markers that improve the performance of CA19-9 in pancreatic cancer
    Zhao, Yun-Peng
    Zhou, Ping-Ting
    Ji, Wei-Ping
    Wang, Hao
    Fang, Meng
    Wang, Meng-Meng
    Yin, Yue-Peng
    Jin, Gang
    Gao, Chun-Fang
    CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 17 (01) : 9 - 18
  • [36] ITRAQ-based quantitative proteomics to reveal Apolipoprotein A-I and Transferrin as potential serum markers in CA19-9 negative pancreatic ductal adenocarcinoma.
    Wu, Wenchuan
    Lin, Chao
    Zhao, Guochao
    Wang, Dansong
    Lou, Wenhui
    Qin, Xinyu
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [37] Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma
    Ferrone, Cristina R.
    Finkelstein, Dianne M.
    Thayer, Sarah P.
    Muzikansky, Alona
    Fernandez-del Castillo, Carlos
    Warshaw, Andrew L.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 2897 - 2902
  • [38] Adjusting CA19-9 for biliary obstruction in pancreatic cancer
    Bliss, Lindsay A.
    Pleskow, Douglas K.
    Eskander, Mariam F.
    Yang, Catherine J.
    Miksad, Rebecca A.
    Ng, Sing Chau
    Berzin, Tyler M.
    Sawhney, Mandeep S.
    Chuttani, Ram
    Tseng, Jennifer F.
    CANCER RESEARCH, 2015, 75
  • [39] CA19-9 decorated mucin proteins in pancreatic cancer
    Rothermund-Franklin, Christy A.
    Caffrey, Thomas C.
    Hollingsworth, Michael A.
    CANCER BIOMARKERS, 2008, 4 (03) : 160 - 160
  • [40] Characteristics and prognosis of patients with pancreatic adenocarcinoma not expressing CA19-9: Analysis of the National Cancer Database
    Sugawara, Toshitaka
    Franco, Salvador Rodriguez
    Sherman, Samantha
    Kirsch, Michael J.
    Colborn, Kathryn
    Franklin, Oskar
    Ishida, Jun
    Grandi, Samuele
    Al-Musawi, Mohammed H.
    Gleisner, Ana
    Schulick, Richard D.
    Del Chiaro, Marco
    PANCREATOLOGY, 2024, 24 (08) : 1340 - 1347
12345